Noticias y Actividades de Syndax Pharmaceuticals

Syndax Pharmaceuticals es una de las ...

• Russell 3000;
• TOB Iconic 10,000.

Syndax Pharmaceuticals es una empresa que cotiza bajo el símbolo de cotización SNDX (US).

Ver el organigrama con sus 16 ejecutivos principales

Biografías más buscadas en Syndax Pharmaceuticals

• Michael Metzger, Director and Chief Executive Officer
• Jennifer Jarrett, Director
• Pierre Legault, Director

Recientes movimientos de ejecutivos en Syndax Pharmaceuticals

• Catherine Madigan, Chief Medical Officer, abandonará la empresa el 31 de dic.. de 2024  (noticia publicada el 29 de diciembre de 2024).

Crear su alerta
para seguir los movimientos de los ejecutivos en Syndax Pharmaceuticals.

Syndax Pharmaceuticals tiene 1.831 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Eli Lilly (Estados Unidos).

Popular M&A news in Farmacia

• Chimerix and Chimerix have merged  (publicado el 22 de abril de 2025)..
• Imbria Pharmaceuticals acaba de anunciar una recaudación de fondos de 58 millones de dólares. (publicado el 10 de abril de 2025).
• Clario ha NRx Pharmaceuticals adquirido (publicado el 18 de marzo de 2025).

Otros contactos sugeridos en el sector Farmacia

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets en Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer en Adare Pharmaceuticals
• Seth Harrison - Chairman and Director en Braeburn Pharmaceuticals

Saber más sobre el sector Farmacia

Últimos comunicados de prensa de Syndax Pharmaceuticals

• Syndax Announces Participation at Stifel Healthcare Conference | Syndax Pharmaceuticals, Inc.
• Syndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis | Syndax Pharmaceuticals, Inc.
• Syndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023 | Syndax Pharmaceuticals, Inc.
• Syndax Announces Participation at the Citi 18th Annual BioPharma Conference | Syndax Pharmaceuticals, Inc.
• Syndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update | Syndax Pharmaceuticals, Inc.
• Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease | Syndax Pharmaceuticals, Inc.
• Syndax to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 3, 2023 | Syndax Pharmaceuticals, Inc.
• Syndax to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 8, 2022 | Syndax Pharmaceuticals, Inc.
• Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) | Syndax Pharmaceuticals, Inc.
• Syndax Pharmaceuticals Announces Appointment of Keith A. Goldan as Chief Financial Officer | Syndax Pharmaceuticals, Inc.
• View more press releases Close

Redes sociales sobre Syndax Pharmaceuticals

• Syndax Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
• Syndax Pharmaceuticals en LinkedIn, Twitter y YouTube